Charles M. Beasley
Lilly Research Laboratories
Lilly Corporate Center
Indianapolis
USA
Name/email consistency: high
- Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. Beasley, C.M., Ball, S.G., Nilsson, M.E., Polzer, J., Tauscher-Wisniewski, S., Plewes, J., Acharya, N. J. Clin. Psychopharmacol (2007)
- All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. Beasley, C.M., Stauffer, V.L., Liu-Seifert, H., Taylor, C.C., Dunayevich, E., Davis, J.M. J. Clin. Psychopharmacol (2007)
- The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. Beasley, C.M., Mitchell, M.I., Dmitrienko, A.A., Emmick, J.T., Shen, W., Costigan, T.M., Bedding, A.W., Turik, M.A., Bakhtyari, A., Warner, M.R., Ruskin, J.N., Cantilena, L.R., Kloner, R.A. J. Am. Coll. Cardiol. (2005)
- A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Beasley, C.M., Sutton, V.K., Hamilton, S.H., Walker, D.J., Dossenbach, M., Taylor, C.C., Alaka, K.J., Bykowski, D., Tollefson, G.D. J. Clin. Psychopharmacol (2003)